Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by A. Quan
Công an TPHCM: Bắt lãnh đạo, nhân viên Công ty mua bán nợ Nhất Tín, 'khủng bố' để đòi khoản nợ 70 tỷ đồng, ăn chia 30%-50%
Thực hiện chỉ đạo của Ban Giám đốc Công an TPHCM về việc điều tra mở rộng vụ án, Cơ quan Cảnh sát điều tra (Phòng Cảnh sát hình sự) xác định thêm hành vi “Cưỡng đoạt tài sản” do một nhóm đối tượng thuộc Công ty TNHH Mua bán nợ Nhất Tín cấu kết thực hiện, xảy ra tại phường Tam Long và khu vực chợ Bà Rịa, Thành phố Hồ Chí Minh.
Công an TPHCM bắt giam diễn viên Trương Ngọc Ánh để điều tra về hành vi lạm dụng tín nhiệm chiếm đoạt hàng ngàn lượng vàng
Trước đó, Công ty Cổ phần Bất động sản Đất Rồng (địa chỉ: 25 Đào Duy Anh, phường Đức Nhuận, TPHCM) có đơn tố cáo Trương Ngọc Ánh - người từng giữ chức vụ Chủ tịch Hội đồng quản trị kiêm Giám đốc Công ty - có dấu hiệu chiếm đoạt tài sản của doanh nghiệp. Theo đó, Công ty TNHH BĐS Đất Rồng được thành lập năm 2007 do Trương Ngọc Ánh làm Giám đốc, người đại diện theo pháp luật.
EFFECTS OF ICOSAPENT ETHYL ON VASCULAR REGENERATIVE CELLS IN INDIVIDUALS WITH ELEVATED TRIGLYCERIDES: INSIGHTS FROM THE IPE-PREVENTION CARDIOLINK-14 TRIAL
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
EMPAGLIFLOZIN IMPROVES VASCULAR REGENERATIVE CELL CONTENT IN PEOPLE WITHOUT DIABETES
BACKGROUND Originally conceived as an antihyperglycemic agent and then approved for lowering the risk of cardiovascular death in adults living with type 2 diabetes (T2D) and known cardiovascular disease, the sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin is now approved for reducing heart failure hospitalizations and is under review for decreasing the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease.
GLP-1RA THERAPY IS ASSOCIATED WITH HIGHER VASCULAR REGENERATIVE CELL CONTENT AND LOWER INFLAMMATORY BURDEN IN PEOPLE LIVING WITH TYPE 2 DIABETES
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
IMPACT OF DIABETES AND GLUCOSE-LOWERING THERAPY ON POST-OPERATIVE ATRIAL FIBRILLATION AFTER CARDIAC SURGERY: SECONDARY ANALYSIS OF THE SEARCH-AF CARDIOLINK-1 RANDOMIZED CLINICAL TRIAL
Diabetes mellitus is an important risk factor for atrial fibrillation (AF) and is associated with an increased risk of complications for patients with AF. The impact of diabetes on post-operative AF after cardiac surgery is not well-defined.
LEFT VENTRICULAR MASS PREDICTS CARDIAC REVERSE REMODELING IN PATIENTS TREATED WITH EMPAGLIFLOZIN: AN EXPLORATORY SUB-ANALYSIS OF THE EMPA-HEART CARDIOLINK-6 RANDOMIZED CONTROLLED TRIAL
Left ventricular (LV) hypertrophy is associated with an elevated risk for cardiovascular (CV) disease events and all-cause mortality. The CV benefits of sodium-glucose transport protein 2 inhibitors (SGLT2i) have been attributed, in part, to cardiac reverse remodeling. The EMPA-HEART CardioLink-6 study reported that SGLT2 inhibition with empagliflozin was associated with a significant reduction in LV mass indexed to body surface area (LVMi) after 6 months.
VALVULAR SURGERY IS ASSOCIATED WITH AN INCREASED RISK OF POST-OPERATIVE ATRIAL FIBRILLATION: SECONDARY ANALYSIS OF THE SEARCH-AF CARDIOLINK-1 RANDOMIZED TRIAL
Patients undergoing valve surgery have a higher risk of developing post-operative atrial fibrillation (POAF) relative to those undergoing isolated coronary artery bypass grafting (CABG). Whether this risk extends beyond hospital discharge is unknown.
THE IMPACT OF STATIN ON POST-OPERATIVE ATRIAL FIBRILLATION AFTER DISCHARGE FROM CARDIAC SURGERY: SECONDARY ANALYSIS OF THE SEARCH-AF CARDIOLINK-1 RANDOMIZED TRIAL
TEMPORAL TRENDS OF THE PREVALENCE OF ISCHEMIA WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE (INOCA) IN ALBERTA, CANADA
A NOVEL ROLE OF SGLT2 INHIBITORS TO INCREASE CIRCULATING PROANGIOGENIC PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE: A SUB-STUDY OF THE EMPA-HEART CARDIOLINK-6 TRIAL
Expand allCollapse all Background SGLT2 inhibitors have been demonstrated to reduce major adverse cardiovascular events and mortality in patients with type 2 diabetes (T2D) who are at high risk for cardiovascular disease (CVD). However, the mechanisms underlying these cardioprotective effects remain unclear.
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease
What is known and objective Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications. Studies have indicated that patients with T2DM have impaired clopidogrel‐induced antiplatelet effect. Ticagrelor and prasugrel are two latest generation P2Y inhibitors with advantageous platelet inhibitory profiles. However, the pharmacodynamic differences between the two drugs in patients with T2DM remain poorly explored.
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease
What is known and objective Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications. Studies have indicated that patients with T2DM have impaired clopidogrel-induced antiplatelet effect. Ticagrelor and prasugrel are two latest generation P2Y inhibitors with advantageous platelet inhibitory profiles. However, the pharmacodynamic differences between the two drugs in patients with T2DM remain poorly explored.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with A.
Contact A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack